Illumina, Inc. $ILMN Shares Bought by Lido Advisors LLC

Lido Advisors LLC increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 61.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,084 shares of the life sciences company’s stock after acquiring an additional 2,698 shares during the period. Lido Advisors LLC’s holdings in Illumina were worth $1,939,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Keybank National Association OH lifted its position in Illumina by 1.5% in the third quarter. Keybank National Association OH now owns 376,809 shares of the life sciences company’s stock worth $103,125,000 after purchasing an additional 5,682 shares during the period. 71 West Capital Partners acquired a new position in shares of Illumina during the 3rd quarter valued at $412,000. Gryphon Financial Partners LLC acquired a new position in shares of Illumina during the 3rd quarter valued at $252,000. Fulcrum Asset Management LLP increased its position in shares of Illumina by 3,405.8% during the 3rd quarter. Fulcrum Asset Management LLP now owns 31,447 shares of the life sciences company’s stock valued at $8,554,000 after purchasing an additional 30,550 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Illumina by 1,643.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 18,826 shares of the life sciences company’s stock worth $5,002,000 after buying an additional 17,746 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 1.2%

Shares of ILMN stock traded down $2.54 during trading on Friday, hitting $207.01. 1,229,158 shares of the company were exchanged, compared to its average volume of 2,291,458. The business’s 50-day simple moving average is $249.02 and its 200 day simple moving average is $179.64. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. Illumina, Inc. has a twelve month low of $112.65 and a twelve month high of $309.35. The firm has a market capitalization of $31.30 billion, a price-to-earnings ratio of 35.63, a P/E/G ratio of 2.84 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 earnings per share. As a group, analysts forecast that Illumina, Inc. will post 5.43 EPS for the current fiscal year.

Insider Transactions at Illumina

In other news, Director Keith Meister sold 98,833 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was sold at an average price of $216.87, for a total transaction of $21,433,912.71. Following the completion of the sale, the director owned 208,826 shares in the company, valued at approximately $45,288,094.62. This represents a 32.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Scott Ericksen sold 267 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the transaction, the chief accounting officer directly owned 14,029 shares in the company, valued at approximately $3,054,955.04. This represents a 1.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,881,899 shares of company stock valued at $415,905,954 in the last ninety days. Insiders own 2.90% of the company’s stock.

More Illumina News

Here’s some of the latest news about ILMN:

• Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
• Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
• Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing

Analyst Upgrades and Downgrades

ILMN has been the subject of several research analyst reports. Canaccord Genuity Group upped their price objective on Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a report on Monday, October 19th. Stephens cut Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price for the company. in a research note on Friday, October 23rd. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $135.00 to $260.00 in a report on Wednesday, September 9th. JPMorgan Chase & Co. dropped their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Finally, Piper Sandler boosted their price target on shares of Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $244.24.

About Illumina

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.